Systemic Sclerosis
Conditions
Keywords
systemic sclerosis autoantibodies
Brief summary
This study is to determine if subjects with .systemic sclerosis have stimulatory autoantibodies to the PDGF receptor and to confirm activation (phosphorylation) of the PDGF receptor in skin sites with varying degrees of skin thickening
Detailed description
Pilot study to assess whether patients with systemic sclerosis have stimulatory autoantibodies to the PDGF receptor and to confirm activation (phosphorylation) of the PDGF receptor in skin sites with varying degrees of skin thickening
Interventions
None listed
Sponsors
Pfizer
University of Michigan
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
1. Fulfill the American College of Rheumatology criteria for systemic sclerosis or: 2. Have no diseases that result in primary fibrosis of an organ system, including the skin and do not have an autoimmune disease
Exclusion criteria
1. If the subject has systemic sclerosis resulting from an environmental exposure 2. If the subject has an autoimmune disease excluding scleroderma 3. If the subject has an active infection (including, but not limited to hepatitis B, hepatitis C and HIV) 4. If the subject has been treated with cyclophosphamide in the past 8 weeks. 5. If the subject is prone to bleeding because they are on medications that thin the blood or have a low platelet count.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stimulatory autoantibodies to the PDGF receptor | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Phosphorylation of the PDGF receptor in patients with systemic sclerosis | One year |
Countries
United States
Outcome results
None listed